Open Access

Skeletal muscle quality as assessed by CT-derived skeletal muscle density is associated with 6-month mortality in mechanically ventilated critically ill patients

  • Wilhelmus G. P. M. Looijaard1, 2, 6Email authorView ORCID ID profile,
  • Ingeborg M. Dekker3,
  • Sandra N. Stapel1, 2,
  • Armand R. J. Girbes1, 2,
  • Jos W. R. Twisk4,
  • Heleen M. Oudemans-van Straaten1, 2 and
  • Peter J. M. Weijs1, 3, 5
Critical Care201620:386

DOI: 10.1186/s13054-016-1563-3

Received: 26 July 2016

Accepted: 8 November 2016

Published: 1 December 2016

Abstract

Background

Muscle quantity at intensive care unit (ICU) admission has been independently associated with mortality. In addition to quantity, muscle quality may be important for survival. Muscle quality is influenced by fatty infiltration or myosteatosis, which can be assessed on computed tomography (CT) scans by analysing skeletal muscle density (SMD) and the amount of intermuscular adipose tissue (IMAT). We investigated whether CT-derived low skeletal muscle quality at ICU admission is independently associated with 6-month mortality and other clinical outcomes.

Methods

This retrospective study included 491 mechanically ventilated critically ill adult patients with a CT scan of the abdomen made 1 day before to 4 days after ICU admission. Cox regression analysis was used to determine the association between SMD or IMAT and 6-month mortality, with adjustments for Acute Physiological, Age, and Chronic Health Evaluation (APACHE) II score, body mass index (BMI), and skeletal muscle area. Logistic and linear regression analyses were used for other clinical outcomes.

Results

Mean APACHE II score was 24 ± 8 and 6-month mortality was 35.6%. Non-survivors had a lower SMD (25.1 vs. 31.4 Hounsfield Units (HU); p < 0.001), and more IMAT (17.1 vs. 13.3 cm2; p = 0.004). Higher SMD was associated with a lower 6-month mortality (hazard ratio (HR) per 10 HU, 0.640; 95% confidence interval (CI), 0.552–0.742; p < 0.001), and also after correction for APACHE II score, BMI, and skeletal muscle area (HR, 0.774; 95% CI, 0.643–0.931; p = 0.006). Higher IMAT was not significantly associated with higher 6-month mortality after adjustment for confounders. A 10 HU increase in SMD was associated with a 14% shorter hospital length of stay.

Conclusions

Low skeletal muscle quality at ICU admission, as assessed by CT-derived skeletal muscle density, is independently associated with higher 6-month mortality in mechanically ventilated patients. Thus, muscle quality as well as muscle quantity are prognostic factors in the ICU.

Trial registration

Retrospectively registered (initial release on 06/23/2016) at ClinicalTrials.gov: NCT02817646.

Keywords

Intensive care unit Computed tomography CT Muscle Muscle quality Myosteatosis Skeletal muscle density Intermuscular adipose tissue Mortality Outcome

Background

Muscle wasting is a severe complication of critical illness [1]. Puthucheary et al. reported a steady decrease in skeletal muscle mass of almost 20% during the first 10 days of intensive care unit (ICU) admission [2]. Loss of muscle has been associated with longer duration of mechanical ventilation and higher ICU and hospital mortality [35]. If patients survive, they exhibit long-term functional disability with a great impact on quality of life for as long as 5 to 8 years after admission [68]. However, many patients already have a low muscle quantity upon admission to the ICU. In two retrospective studies as much as 60–70% of patients had low muscle quantity as assessed on computed tomography (CT) scans on ICU admission, and low muscle quantity at ICU admission was associated with a higher mortality [9, 10].

Not only the quantity, but also the quality of muscle seems important [11]. Along with a decline in muscle mass, fatty infiltration of muscles or myosteatosis has been identified as a possible cause of loss of muscle quality [11]. Myosteatosis can be apparent within muscle fibres and evaluated on CT scans by measuring skeletal muscle density (SMD), or between muscle fibres and evaluated on CT scans by measuring the amount of adipose tissue between muscles (also termed intermuscular adipose tissue or IMAT). A lower SMD was associated with increased lipid infiltration in muscle biopsies and poor clinical outcomes in non-ICU populations [1214]. Additionally, a recent study in critically ill patients using ultrasound of the quadriceps muscle found that not only a decrease in muscle quantity but also increased muscle echogenicity was related to a decrease in muscle function [15]. An increased amount of IMAT as assessed on CT scans has been associated with decreased muscle function and increased (systemic) inflammation in non-ICU populations [16, 17]. The aim of the present study was to investigate if muscle quality, as assessed by CT-derived SMD and IMAT, is associated with mortality independently of muscle quantity and severity of illness. We hypothesized that low SMD and high IMAT at ICU admission are associated with a poor outcome, independent of the quantity of muscle and severity of illness.

Methods

Patients and data

This is a retrospective analysis of CT-derived muscle quality at a single time point at ICU admission in critically ill patients admitted to a mixed medical-surgical ICU of a university hospital from September 2003 to April 2013. Patients were included if they were aged 18 years or older, stayed in the ICU for at least 4 days, required mechanical ventilation during their ICU stay, and had an abdominal CT scan made 1 day before or up to 4 days after admission to the ICU. Patients were excluded if the CT scan was not eligible for analysis, or if data on body weight or height or the Acute Physiological, Age, and Chronic Health Evaluation (APACHE) II score was missing. By searching the hospital information system for any patients meeting inclusion criteria, we expanded our previously reported cohort of ICU patients [9].

Patient data including age, sex, weight, height, admission diagnosis, APACHE II score, length of ventilation (LOV), ICU length of stay (ICU-LOS) and hospital length of stay (hospital-LOS), discharge destination, and ICU and hospital mortality was obtained from the ICU patient data management system (Metavision; IMDsoft, Tel-Aviv, Israel) and the hospital information system (Mirador; iSOFT Nederland BV, Leiden, The Netherlands). If mortality data were not registered, these were collected from the civil registry or from the general practitioner.

CT scan analysis

The precision of single slice CT scan analysis at the third lumbar vertebra (L3) level is high (inter- and intra-observer variability less than 2% in healthy volunteers) [18]. Both skeletal muscle area (r = 0.83–0.99; p < 0.01) and IMAT (r = 0.39–0.61; p < 0.05) at this level are closely related to whole body skeletal muscle and IMAT volumes as assessed by magnetic resonance imaging (MRI) [1921].

CT scans made 1 day before to 4 days after ICU admission for diagnostic purposes were imported from the hospital radiology system and stored on a secure computer system. Scans were analysed using Slice-O-matic versions 4.3 and 5.0 (TomoVision, Montreal, QC, Canada) by two trained and certified investigators (WGPML and IMD, trained by the Cross Cancer Institute, Edmonton, AB, Canada) who had frequent consultation with each other if there was any doubt about eligibility, landmarking, or analysis.

The CT scans were analysed for eligibility and rejected if the scan quality was too low for analysis or if they contained artefacts, or if muscle was cut off due to windowing. Landmarking was performed by identifying the L3 and isolating the CT slice that depicted the whole vertebra the best. A bony landmark was used to ensure reproducibility and consistency between patients.

Different tissues were identified using boundaries in Hounsfield Units (HU) set to –29 to +150 for muscle, –190 to –30 for IMAT and subcutaneous adipose tissue, and –150 to –50 for visceral adipose tissue [22]. SMD was assessed by the mean radiological muscle attenuation of all muscle visible at the L3 level, measured in HU. The HU scale is a radiological scale describing the density of tissues on CT scans [23]. Lower mean muscle attenuation indicates less dense muscle tissue with more lipid infiltration, e.g. lower SMD, while a higher mean muscle attenuation indicates denser muscle tissue with less lipid infiltration, e.g. higher SMD [14]. IMAT was assessed by identifying all visible adipose tissue within muscle fascia in cm2 [22]. Previously found ICU-specific optimal cut-off points related to hospital mortality were used to define low skeletal muscle area: below 170 cm2 for male patients and below 110 cm2 for female patients [9]. See Fig. 1 for an example of CT scan analysis.
Fig. 1

Example of CT scan analysis. This image shows CT scans at the level of lumbar vertebra 3 of two patients both un-analysed (upper row) and analysed (lower row). The analysed images show muscle tissue (red) and intermuscular adipose tissue (IMAT, green). The patient on the left has more muscle (165 vs. 120 cm2), less IMAT (10 vs. 19.5 cm2), and higher mean skeletal muscle density (42 vs. 18 Hounsfield Units) than the patient on the right

Because muscle quality is important for dealing with recovery after ICU and hospital discharge, we chose 6-month mortality as the primary endpoint. Secondary endpoints were the odds of being discharged from the hospital to home, length of ventilation, and ICU and hospital LOS in survivors.

Statistics

Independent sample t tests were used to compare survivors and non-survivors for normally distributed continuous variables, and Mann-Whitney U tests for non-normally distributed continuous variables. Fisher exact and Chi2 tests with post-hoc Bonferroni analysis were used to compare survivors and non-survivors for categorical variables. Kaplan-Meier plots were made to visualize the effect of SMD and IMAT (divided into two groups based on the median) on 6-month mortality, with log-rank tests to compare the survival curves of the two groups. Cox regression analysis was used to evaluate the association between SMD or IMAT (as continuous variables) and 6-month mortality. After univariable analyses, APACHE II score was added to the models to adjust for severity of illness (model 2). In the second adjusted model, body mass index (BMI), and skeletal muscle area were included as well (model 3). Age is included in the APACHE II score and was therefore not separately included in the adjusted models. Additionally, we performed analyses on the subgroup of patients with available data on visceral and subcutaneous adipose tissue in which BMI was substituted with visceral and subcutaneous adipose tissue as a measure of total body fatness (model 4).

Logistic and linear regression analyses were used to evaluate the association between SMD or IMAT and the secondary outcome measures discharge to home, LOV, ICU-LOS, and hospital-LOS in survivors. LOV, ICU-LOS, and hospital-LOS were non-normally distributed and positively skewed; therefore, the analysis was performed on the natural logarithm of the variables. By re-transforming by using the inverse, the influence of a given predictor was calculated as a percentage change in outcome.

IBM SPSS Statistics 22 (IBM Corp, Armonk, NY, USA) was used for statistical analysis. Values are reported as mean ± standard deviation (SD) or median and 25–75% interquartile range (IQR). All statistical tests were two-sided. A p < 0.05 was considered statistically significant.

Results

A total of 13,434 patients were admitted to the ICU during the study period with a mean APACHE II score of 17.4 ± 9.2. Six hundred and seventy-eight patients fulfilled inclusion criteria and had their CT scans imported from the radiology system to be analysed for eligibility. CT scans that were found not to be eligible were due to artefacts (78 scans), muscle cut-off (50 scans), or low quality (47 scans). Finally, 491 patients (72%) with complete clinical data and good quality CT scans were included for the statistical analysis. However, due to windowing or artefacts, visceral and/or subcutaneous adipose tissue could not be analysed in 154 patients. We therefore performed subgroup analyses that included visceral and subcutaneous adipose tissue in a subgroup of 337 patients (50%). Figure 2 is the consort diagram showing the inclusion process.
Fig. 2

Consort diagram showing the inclusion process. CT computed tomography, ICU intensive care unit

Patient characteristics

Patient characteristics are presented in Table 1 for 6-month survivors and non-survivors. Outcome measures are presented separately in Table 2. CT scans were mostly made on the day of admission to the ICU. Three hundred and twelve (64.7%) patients had a low skeletal muscle area at ICU admission. Six-month mortality was 35.6%. Non-survivors were older (67 ± 14 vs. 55 ± 18 years; p < 0.001), had a lower BMI (24.6 ± 4.3 vs. 25.5 ± 4.4 kg/m2; p = 0.042), higher APACHE II score (27 ± 8 vs. 22 ± 8; p < 0.001), and were more often medical patients (62% vs. 43%; p < 0.001) than survivors.
Table 1

Patient characteristics of all patients and comparison between survivors and non-survivors

 

All patients

N = 491

Survivors1

(n = 299)

Non-survivors1

(n = 165)

P value survivors vs. non-survivors

 

Mean/median/n

SD/IQR/%

Mean/median/n

SD/IQR/%

Mean/median/n

SD/IQR/%

 

Age, years

58

±18

55

±18

67

±14

<0.001

Sex, male, n (%)

305

62%

191

64%

93

56%

0.135

BMI, kg/m2

25.2

±4.3

25.5

±4.4

24.6

±4.3

0.042

 Underweight2, n (%)

19

4.1%

11

3.7%

8

4.8%

0.291

 Normal weight2, n (%)

238

51.3%

145

48.5%

93

56.4%

 

 Overweight2, n (%)

158

34.1%

108

36.1%

50

30.3%

 

 Obesity2, n (%)

49

10.6%

35

11.7%

14

8.5%

 

APACHE II score

24

±8

22

±8

27

±8

<0.001

Admission category, n (%)

      

0.001

 Medical

248

50.5%

130

43%

102

62%

 

 Surgical

243

49.5%

169

57%

63

38%

 

Admission diagnosis, n (%)

      

<0.001

 Cardiovascular

32

6.5%

18a

6.0%

14a

8.5%

 

 Metabolic/renal

15

3.1%

8a

2.7%

6a

3.6%

 

 Neurologic

41

8.4%

19a

6.4%

16a

9.7%

 

 Post-resuscitation

28

5.7%

16a

5.4%

11a

6.7%

 

 Post-surgery

149

30.3%

95a

31.8%

50a

30.3%

 

 Respiratory insufficiency

68

13.8%

40a

13.4%

25a

15.2%

 

 Sepsis

31

6.3%

14a

4.7%

15a

9.1%

 

 Trauma

94

19.1%

74a

24.7%

13b

7.9%

 

 Other

33

6.7%

15a

5.0%

15a

9.1%

 

Length of hospital stay before ICU admission, days

0

0–4

0

0–4

0

0–6

0.166

Time from ICU admission to CT scan, days

0

0–1

0

0–1

0

0–1

0.277

Skeletal muscle area, cm2

136.5

±39.0

143.5

±38.9

120.3

±33.0

<0.001

Skeletal muscle index, cm2/m2

44.8

±11.0

46.6

±10.6

40.4

±9.9

<0.001

Low skeletal muscle area3, n (%)

312

63.5%

163

54.5%

137

83.0%

<0.001

SMD, HU

29.9

±11.7

31.4

±11.7

25.1

±9.4

<0.001

IMAT, cm2

13.6

8.4–24.3

13.3

7.9–23.2

17.1

10.5–27.1

0.004

Visceral adipose tissue, cm2 (n = 337)

96.7

49.3–170.6

95.8

50.9–178.1

108.1

54.1–177.5

0.593

Subcutaneous adipose tissue, cm2 (n = 337)

132.7

90.2–182.4

133.7

89.8–189.2

127.7

95.7–176.2

0.440

1Survivors and non-survivors 6 months after ICU admission

2WHO categories: underweight, BMI <18.5; normal weight: BMI 18.5–24.9; overweight: BMI 25–29.9; obesity: BMI ≥30 [42]

3Defined by skeletal muscle area: <170 cm2 for males and <110 cm2 for females [9]

a, bValues in the same row not sharing the same superscript letter are significantly different in a post-hoc Bonferroni analysis

Values in bold indicate statistically significant p values

APACHE Acute Physiological, Age, and Chronic Health Evaluation, BMI, body mass index, CT computed tomography, HU Hounsfield Units, ICU intensive care unit, IMAT intermuscular adipose tissue, IQR interquartile range, SD standard deviation, SMD skeletal muscle density

Table 2

Primary and secondary outcome measures

 

n

%

Days

IQR

Six-month mortality

165

35.6%

  

ICU mortality

84

17.1%

  

Hospital mortality

132

26.9%

  

Length of ventilation

  

11

6–20

ICU length of stay

  

13

7–23

Hospital length of stay

  

35

19–59

Destination after discharge

    

 Home

144

40.7%

  

 Other hospital

80

22.6%

  

 Nursing home

76

21.5%

  

 Rehabilitation unit

45

12.7%

  

 Other

9

2.5%

  

ICU intensive care unit, IQR interquartile range

Mean SMD at ICU admission was 29.9 ± 11.7 HU. Median IMAT at ICU admission was 13.6 (8.4–24.3) cm2, comprising 9.1% of total tissue within muscle fascia (skeletal muscle area plus IMAT) at the L3 level. Non-survivors had a lower skeletal muscle area (120.3 ± 33.0 vs. 143.5 ± 38.9 cm2; p < 0.001), lower SMD (25.1 ± 9.4 vs. 31.4 ± 11.7 HU; p < 0.001), and more IMAT (17.1 (10.5–27.1) vs. 13.3 (7.9–23.2) cm2; p = 0.004) than survivors.

Association between muscle quality and 6-month mortality

Mortality was significantly higher in patients with low muscle quality with SMD values below the median or IMAT values above the median (Fig. 3).
Fig. 3

Kaplan-Meier plots. These graphs illustrate mortality for groups below and above median skeletal muscle density (SMD) (29.2 Hounsfield Units) and median intermuscular adipose tissue (IMAT) (13.6 cm2). ICU intensive care unit

Cox regression analysis showed that higher SMD was associated with lower 6-month mortality (hazard ratio (HR) per 10 HU, 0.640; 95% confidence interval (CI), 0.552–0.742; p < 0.001; Table 3). This association was still apparent when SMD was adjusted for the confounders APACHE II score, BMI, and skeletal muscle area (HR per 10 HU, 0.774; 95% CI, 0.643–0.931; p = 0.006).
Table 3

Cox regression: association between skeletal muscle density or intermuscular adipose tissue and mortality

 

Univariable

N = 491

Model 2

N = 491

Model 3

N = 491

Model 4

(n = 337)

6-month mortality

HR

95% CI

P value

HR

95% CI

P value

HR

95% CI

P value

HR

95% CI

P value

SMD (per 10 HU)

0.640

0.552–0.742

<0.001

0.703

0.605–0.818

<0.001

0.774

0.643–0.931

0.006

0.728

0.571–0.928

0.010

IMAT (per 10 cm2)

1.153

1.042–1.277

0.006

1.092

0.980–1.217

0.110

1.092

0.966–1.236

0.159

1.244

1.048–1.476

0.012

Model 2: adjusted for APACHE II score

Model 3: adjusted for APACHE II score, skeletal muscle area, and BMI

Model 4 (subgroup analysis): adjusted for APACHE II score, skeletal muscle area, visceral adipose tissue, and subcutaneous adipose tissue

Values in bold indicate statistically significant p values

APACHE Acute Physiological, Age, and Chronic Health Evaluation, CI confidence interval, HR hazard ratio, HU Hounsfield Units, IMAT intermuscular adipose tissue, SMD skeletal muscle density

Cox regression analysis showed that higher IMAT was associated with higher 6-month mortality (HR per 10 cm2, 1.153; 95% CI, 1.042–1.277; p = 0.006). However, when adjusted for APACHE II score alone or the confounders APACHE II score, BMI, and skeletal muscle area the association between IMAT and 6-month mortality was not significant (HR per 10 cm2, 1.092; 95% CI, 0.966–1.236; p = 0.159).

Analyses in the subgroup with visceral and subcutaneous adipose tissue

Additional Cox regression analyses were performed in the subgroup of patients with available data on visceral and subcutaneous adipose tissue (n = 337, Table 3). Patients in this subgroup were significantly different from patients in whom visceral and/or subcutaneous adipose tissue could not be analysed. They were younger (56 vs. 64 years; p < 0.001), more often male (66 vs. 55%; p = 0.021), and had a lower BMI (24.8 vs. 25.9 kg/m2; p = 0.026). In this subgroup, we found both SMD (HR per 10 HU, 0.623; 95% CI 0.524–0.739; p < 0.001) and IMAT (HR per 10 cm2, 1.245; 95% CI, 1.106–1.401; p < 0.001) were significantly associated with 6-month mortality. In multivariable analyses both SMD (HR per 10 HU, 0.728; 95% CI, 0.571–0.928; p = 0.010) and IMAT (HR per 10 cm2, 1.244; 95% CI, 1.048–1.476; p = 0.012) remained significantly associated with 6-month mortality, adjusted for APACHE II score, skeletal muscle area, and visceral and subcutaneous adipose tissue.

Secondary outcome measures in survivors

Higher SMD was significantly associated with shorter hospital-LOS after adjustment for APACHE II score, BMI, and skeletal muscle area (Table 4). After re-transformation we found that 10 HU higher SMD was associated with a 14% shorter hospital-LOS. IMAT was not associated with hospital LOS. Neither SMD nor IMAT were significantly associated with the odds of being discharged to home, LOV, or ICU-LOS.
Table 4

Logistic and linear regression: association between skeletal muscle density or intermuscular adipose tissue and secondary outcomes

 

Univariable

Model 2

Model 3

 

OR/B

95% CI

P value

OR/B

95% CI

P value

OR/B

95% CI

P value

Discharge to home

         

 SMD (per 10 HU)

1.039

0.864 to 1.250

0.683

0.990

0.816 to 1.200

0.915

0.926

0.718 to 1.195

0.556

 IMAT (per 10 cm2)

0.886

0.741 to 1.059

0.182

0.912

0.761 to 1.093

0.317

0.884

0.715 to 1.093

0.254

Length of ventilation

         

 SMD (per 10 HU)

–0.038

–0.107 to 0.032

0.292

–0.003

–0.075 to 0.069

0.936

–0.018

–0.111 to 0.075

0.705

 IMAT (per 10 cm2)

0.050

–0.014 to 0.115

0.126

0.029

–0.036 to 0.094

0.384

0.026

–0.049 to 0.101

0.499

Length of ICU stay

         

 SMD (per 10 HU)

–0.051

–0.123 to 0.020

0.158

–0.020

–0.092 to 0.053

0.598

–0.032

–0.128 to 0.063

0.506

 IMAT (per 10 cm2)

0.064

–0.003 to 0.130

0.059

0.043

–0.023 to 0.110

0.199

0.041

–0.036 to 0.119

0.292

Length of hospital stay

         

 SMD (per 10 HU)

–0.123

–0.192 to –0.054

0.001

–0.112

–0.184 to –0.041

0.002

–0.134

–0.228 to –0.040

0.005

 IMAT (per 10 cm2)

0.075

0.010 to 0.140

0.023

0.065

–0.001 to 0.131

0.052

0.064

–0.012 to 0.141

0.100

Model 2: adjusted for APACHE II score

Model 3: adjusted for APACHE II score, skeletal muscle area, and BMI

Discharge to home results are given as OR; length of ventilation, ICU, and hospital stay are given as B values

Values in bold indicate statistically significant p values

APACHE Acute Physiological, Age, and Chronic Health Evaluation, B beta coefficient, CI confidence interval, HU Hounsfield Units, ICU intensive care unit, IMAT intermuscular adipose tissue, OR odds ratio, SMD skeletal muscle density

Discussion

This retrospective study in mechanically ventilated patients admitted to the ICU for 4 days or longer shows that low skeletal muscle quality at ICU admission, as assessed by skeletal muscle density on CT scans, is associated with higher 6-month mortality independent of muscle quantity, APACHE II score, and BMI. A lower SMD was also associated with a longer hospital stay in survivors. This is the first study investigating the relation between CT-derived markers for muscle quality and outcome in ventilated critically ill patients. Intermuscular adipose tissue was also associated with mortality but not independently, suggesting that SMD is a stronger marker of muscle quality for 6-month mortality or that IMAT is better represented by confounders than SMD.

Muscle quality and quantity

Previously we have found that low muscle quantity as assessed by skeletal muscle area on CT scans at ICU admission is a risk factor for hospital mortality, independent of sex and APACHE II score [9]. These findings were in line with a study by Moisey et al. in elderly injured ICU patients, who found low skeletal muscle area to be associated with higher mortality and less ventilator-free and ICU-free days [10]. In the present study, we found that the quality of muscle appeared to be important for survival in addition to quantity.

The APACHE II score is the best validated prognostic ICU score for hospital mortality incorporating age, comorbidities, and acute illness. However, it appears that, independently of APACHE II score, a poor health status as reflected by low muscle quantity and quality (whether due to inactivity, comorbidity, or high age) are important prognostic markers. Unfortunately, the updated APACHE III and IV scores were not available for all patients.

Of interest, IMAT was independently associated with 6-month mortality in a subgroup, but not in the entire cohort. The patients in the subgroup were younger, more often male, and had a lower BMI. Apparently, visceral tissue on CT scans can more often not be analysed in older patients with high BMI, mostly because a part of the scan is often cut-off in the windowing process.

Causes and consequences of myosteatosis

Previous studies have shown that inactivity, as seen in pre-existing illness and advancing age, can cause an increase in myosteatosis (as seen by a decrease in SMD and an increase in IMAT) and that these changes are associated with decreased muscle strength [2426]. During inactivity there is a decrease in lipoprotein lipase activity, the rate-limiting enzyme in triglyceride metabolism, which hydrolyses triglycerides into lipoproteins [27, 28]. Additionally, during bed rest a decrease in 3-hydroxyacyl-CoA-dehydrogenase concentration is seen, which impairs the muscle’s ability to metabolize free fatty acids to acyl-CoA [29, 30]. Finally, denervation causes an increase in malonyl-CoA concentrations, which in turn inhibits the rate-limiting enzyme responsible for transporting acyl-CoA into the mitochondria [31]. These altered metabolic mechanisms associated with inactivity decrease the ability of muscles to oxidise lipids and promotes a shift in muscle fuel utilisation from lipids towards glucose, causing accumulation of lipids in the muscle [26, 32]. Manini et al. found that 4 weeks of lower limb immobilisation in healthy adults caused an increase in IMAT and a loss in muscle strength independent of a decrease in muscle mass [26]. Their findings support the idea that myosteatosis is related to decreased muscle quality.

Adipose tissue has been noted as a major endocrine organ. To date, hundreds of adipokines, cytokines secreted by adipose tissue, have been identified [33]. Myosteatosis is associated with an upregulation of macrophage and T-cell expression [34]. These inflammatory cells produce pro-inflammatory cytokines such as tumour necrosis factor-alpha (TNFα) and interleukin-6 (IL-6) [35] which mediate contractile dysfunction [36, 37] and create a low-grade inflammatory environment in which the metabolic syndrome, cardiovascular disease, and insulin resistance are prone to develop [16, 17, 34].

Muscle wasting and long-term outcome

Previous studies have shown that muscle wasting as occurring during critical illness has a large impact on survival, successful weaning from ventilation, and long-term functioning [38, 38]. Herridge et al. found functional disability in survivors of acute respiratory distress syndrome as much as 5 years after admission to the ICU [7] and Iwashyna et al. found functional limitations up to 8 years after severe sepsis [8]. A decrease in muscle quality as assessed by CT scans has been described in 15 patients in a small substudy of the EPaNIC trial where a substantial decrease in skeletal muscle area and SMD, and an increase in IMAT developing over a 7-day period during the early stage of critical illness was found [39]. In two observational studies including 136 and 115 patients requiring at least 5 and 7 days of mechanical ventilation, respectively, muscle weakness acquired during critical illness was associated with increased ICU and hospital mortality [3, 38]. Our study found that low muscle quality present at the beginning of critical illness was already associated with poor outcome, before the devastating effects of critical illness on muscle wasting.

Strengths and limitations

Our study has strengths and limitations. This is the first study up to now investigating the relation between muscle quality assessed with CT scans and clinical outcomes in a large group of critically ill ventilated patients. However, we only included patients who had a CT scan made and the resulting selection bias might limit the generalizability of our findings to the overall ICU population. The APACHE II score of the study population was higher than the overall ICU population, all patients were ventilated, and had an ICU length of stay of at least 4 days, indicating that the study patients were severely ill. Low muscle quality at admission likely has greater impact in the more severely ill patients, because the effect of additional critical illness-related muscle wasting is greater in this population.

Muscle quality is typically defined as muscle strength per unit of muscle mass or cross-sectional area. However, measuring muscle strength in ventilated critically ill patients is not feasible. Therefore, we used SMD and IMAT as proxy markers for muscle quality [40]. To date, SMD on CT scans has been related to myosteatosis [14, 23]. However, in recent studies in ICU patients using ultrasound, a relation between ultrasound echogenicity and myonecrosis in muscle biopsies has been found [2, 41]. Changes in SMD on CT scans might therefore not only reflect myosteatosis, but also myonecrosis. A prospective study using CT scans and muscle biopsies will have to further elucidate which changes in muscle are reflected by SMD in ICU patients.

A further limitation to our study is its observational design, precluding any deduction of causality. In addition, the complexity of critical illness may obscure residual confounding. Finally, the focus of our study was the prediction of long-term mortality at ICU admission, e.g. whether muscle quality at admission is a predictor of long-term mortality independent of muscle mass and of the best validated predictive score (APACHE). Further studies are needed to determine the risk factors for poor muscle quality and to determine the additional impact of ICU-acquired weakness on long-term mortality.

Conclusions

Low skeletal muscle quality at ICU admission, as assessed by skeletal muscle density on CT scans, is associated with higher 6-month mortality in mechanically ventilated patients, independent of muscle quantity, APACHE II score, and BMI. Low muscle quality was also associated with longer hospital length of stay in survivors. Therefore, muscle quality appears to be as important for outcome as muscle quantity. Future intervention studies, including nutrition and early exercise, should not only focus on preventing further deterioration of muscle quantity, but also of muscle quality.

Abbreviations

APACHE: 

Acute Physiological, Age, and Chronic Health Evaluation

BMI: 

Body mass index

CI: 

Confidence interval

CT: 

Computed tomography

Hospital-LOS: 

Hospital length of stay

HR: 

Hazard ratio

HU: 

Hounsfield Units

ICU: 

Intensive care unit

ICU-LOS: 

ICU length of stay

IMAT: 

Intermuscular adipose tissue

LOV: 

Length of ventilation

SMD: 

Skeletal muscle density

Declarations

Acknowledgements

We thank Ronald Driessen from the Department of Intensive Care Medicine for his contribution in the collection of data.

Funding

A research grant provided by Baxter Healthcare was used for acquisition of CT scan analysis software and for a part of CT scan analysis. The funding source was not involved in any aspect of the design of the study, nor in collection, analysis, and interpretation of data, nor in manuscript preparation.

Availability of data and materials

The datasets generated and analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

WGPML, HMO-vS and PJMW designed research; WGPML and IMD collected data; ARJG and SNS provided essential resources; WGPML, PJMW, HMO-vS, and JWRT analysed the data; WGPML, HMO-vS, and PJMW wrote the paper; WGPML had primary responsibility for final content. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

All images in this manuscript are entirely unidentifiable and do not include any personal details, therefore no consent for publication was obtained.

Ethics approval and consent to participate

The study was approved by the Institutional Review Board of the VU University Medical Center (identification number 2012/243). The need for informed consent was waived because of the retrospective nature of the study using only data obtained from standard care.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Intensive Care Medicine, VU University Medical Center Amsterdam
(2)
Institute for Cardiovascular Research, VU University Medical Center Amsterdam
(3)
Department of Nutrition and Dietetics, Internal Medicine, VU University Medical Center Amsterdam
(4)
Department of Epidemiology and Biostatistics, VU University Medical Center Amsterdam
(5)
Department of Nutrition and Dietetics, Amsterdam University of Applied Sciences
(6)
VU University Medical Center Amsterdam

References

  1. Hermans G, Van den Berghe G. Clinical review: intensive care unit acquired weakness. Crit Care. 2015;19:274.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310:1591–600.View ArticlePubMedGoogle Scholar
  3. Ali NA, O'Brien Jr JM, Hoffmann SP, Phillips G, Garland A, Finley JC, et al. Acquired weakness, handgrip strength, and mortality in critically ill patients. Am J Respir Crit Care Med. 2008;178:261–8.View ArticlePubMedGoogle Scholar
  4. De Jonghe B, Sharshar T, Lefaucheur JP, Authier FJ, Durand-Zaleski I, Boussarsar M, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA. 2002;288:2859–67.View ArticlePubMedGoogle Scholar
  5. De Jonghe B, Bastuji-Garin S, Durand MC, Malissin I, Rodrigues P, Cerf C, et al. Respiratory weakness is associated with limb weakness and delayed weaning in critical illness. Crit Care Med. 2007;35:2007–15.View ArticlePubMedGoogle Scholar
  6. Wieske L, Dettling-Ihnenfeldt DS, Verhamme C, Nollet F, van Schaik IN, Schultz MJ, et al. Impact of ICU-acquired weakness on post-ICU physical functioning: a follow-up study. Crit Care. 2015;19:196.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364:1293–304.View ArticlePubMedGoogle Scholar
  8. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304:1787–94.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Weijs PJ, Looijaard WG, Dekker IM, Stapel SN, Girbes AR, Oudemans-van Straaten HM, et al. Low skeletal muscle area is a risk factor for mortality in mechanically ventilated critically ill patients. Crit Care. 2014;18:R12.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Moisey LL, Mourtzakis M, Cotton BA, Premji T, Heyland DK, Wade CE, et al. Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients. Crit Care. 2013;17:R206.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Goodpaster BH, Carlson CL, Visser M, Kelley DE, Scherzinger A, Harris TB, et al. Attenuation of skeletal muscle and strength in the elderly: The Health ABC Study. J Appl Physiol (1985). 2001;90:2157–65.Google Scholar
  12. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539–47.View ArticlePubMedGoogle Scholar
  13. Antoun S, Lanoy E, Iacovelli R, Albiges-Sauvin L, Loriot Y, Merad-Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119:3377–84.View ArticlePubMedGoogle Scholar
  14. Goodpaster BH, Kelley DE, Thaete FL, He J, Ross R. Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J Appl Physiol (1985). 2000;89:104–10.Google Scholar
  15. Parry SM, El-Ansary D, Cartwright MS, Sarwal A, Berney S, Koopman R, et al. Ultrasonography in the intensive care setting can be used to detect changes in the quality and quantity of muscle and is related to muscle strength and function. J Crit Care. 2015;30:1151. e9–14.View ArticlePubMedGoogle Scholar
  16. Addison O, Marcus RL, Lastayo PC, Ryan AS. Intermuscular fat: a review of the consequences and causes. Int J Endocrinol. 2014;2014:309570.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Coen PM, Goodpaster BH. Role of intramyocelluar lipids in human health. Trends Endocrinol Metab. 2012;23:391–8.View ArticlePubMedPubMed CentralGoogle Scholar
  18. MacDonald AJ, Greig CA, Baracos V. The advantages and limitations of cross-sectional body composition analysis. Curr Opin Support Palliat Care. 2011;5:342–9.View ArticlePubMedGoogle Scholar
  19. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (1985). 2004;97:2333–8.View ArticleGoogle Scholar
  20. Schweitzer L, Geisler C, Pourhassan M, Braun W, Gluer CC, Bosy-Westphal A, et al. What is the best reference site for a single MRI slice to assess whole-body skeletal muscle and adipose tissue volumes in healthy adults? Am J Clin Nutr. 2015;102:58–65.View ArticlePubMedGoogle Scholar
  21. Ruan XY, Gallagher D, Harris T, Albu J, Heymsfield S, Kuznia P, et al. Estimating whole body intermuscular adipose tissue from single cross-sectional magnetic resonance images. J Appl Physiol (1985). 2007;102:748–54.View ArticleGoogle Scholar
  22. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.View ArticlePubMedGoogle Scholar
  23. Aubrey J, Esfandiari N, Baracos VE, Buteau FA, Frenette J, Putman CT, et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol (Oxf). 2014;210:489–97.View ArticleGoogle Scholar
  24. Baracos V, Kazemi-Bajestani SM. Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. Int J Biochem Cell Biol. 2013;45:2302–8.View ArticlePubMedGoogle Scholar
  25. Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Mieyer P, et al. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr. 2009;90:1579–85.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Manini TM, Clark BC, Nalls MA, Goodpaster BH, Ploutz-Snyder LL, Harris TB. Reduced physical activity increases intermuscular adipose tissue in healthy young adults. Am J Clin Nutr. 2007;85:377–84.PubMedGoogle Scholar
  27. Zderic TW, Hamilton MT. Physical inactivity amplifies the sensitivity of skeletal muscle to the lipid-induced downregulation of lipoprotein lipase activity. J Appl Physiol (1985). 2006;100:249–57.View ArticleGoogle Scholar
  28. Bey L, Hamilton MT. Suppression of skeletal muscle lipoprotein lipase activity during physical inactivity: a molecular reason to maintain daily low-intensity activity. J Physiol. 2003;551:673–82.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Hikida RS, Gollnick PD, Dudley GA, Convertino VA, Buchanan P. Structural and metabolic characteristics of human skeletal muscle following 30 days of simulated microgravity. Aviat Space Environ Med. 1989;60:664–70.PubMedGoogle Scholar
  30. Ferretti G, Antonutto G, Denis C, Hoppeler H, Minetti AE, Narici MV, et al. The interplay of central and peripheral factors in limiting maximal O2 consumption in man after prolonged bed rest. J Physiol. 1997;501(Pt 3):677–86.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Wagenmakers AJ. A malonyl-CoA fuel sensing mechanism in muscle: effects of insulin, glucose and denervation. Clin Nutr. 1996;15:144–5.View ArticlePubMedGoogle Scholar
  32. Stein TP, Wade CE. Metabolic consequences of muscle disuse atrophy. J Nutr. 2005;135:1824s–8s.Google Scholar
  33. Lehr S, Hartwig S, Sell H. Adipokines: a treasure trove for the discovery of biomarkers for metabolic disorders. Proteomics Clin Appl. 2012;6:91–101.View ArticlePubMedGoogle Scholar
  34. Khan IM, Perrard XY, Brunner G, Lui H, Sparks LM, Smith SR, et al. Intermuscular and perimuscular fat expansion in obesity correlates with skeletal muscle T cell and macrophage infiltration and insulin resistance. Int J Obes (Lond). 2015;39:1607–18.View ArticleGoogle Scholar
  35. Lee DE, Kehlenbrink S, Lee H, Hawkins M, Yudkin JS. Getting the message across: mechanisms of physiological cross talk by adipose tissue. Am J Physiol Endocrinol Metab. 2009;296:E1210–29.View ArticlePubMedGoogle Scholar
  36. Reid MB, Lannergren J, Westerblad H. Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med. 2002;166:479–84.View ArticlePubMedGoogle Scholar
  37. Wilcox P, Osborne S, Bressler B. Monocyte inflammatory mediators impair in vitro hamster diaphragm contractility. Am Rev Respir Dis. 1992;146:462–6.View ArticlePubMedGoogle Scholar
  38. Sharshar T, Bastuji-Garin S, Stevens RD, Durand MC, Malissin I, Rodriguez P, et al. Presence and severity of intensive care unit-acquired paresis at time of awakening are associated with increased intensive care unit and hospital mortality. Crit Care Med. 2009;37:3047–53.View ArticlePubMedGoogle Scholar
  39. Casaer MP, Langouche L, Coudyzer W, Vanbeckevoort D, De Dobbelaer B, Guiza FG, et al. Impact of early parenteral nutrition on muscle and adipose tissue compartments during critical illness. Crit Care Med. 2013;41:2298–309.View ArticlePubMedGoogle Scholar
  40. McGregor RA, Cameron-Smith D, Poppitt SD. It is not just muscle mass: a review of muscle quality, composition and metabolism during ageing as determinants of muscle function and mobility in later life. Longev Healthspan. 2014;3:9.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Puthucheary ZA, Phadke R, Rawal J, McPhail MJ, Sidhu PS, Rowlerson A, et al. Qualitative ultrasound in acute critical illness muscle wasting. Crit Care Med. 2015;43:1603–11.View ArticlePubMedGoogle Scholar
  42. World Health Organization. Obesity: preventing and managing the global epedemic: report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i-253.Google Scholar

Copyright

© The Author(s). 2016

Advertisement